Clinical value of oral contrast-enhanced ultrasonography in diagnosis of gastric tumors
- PMID: 38292839
- PMCID: PMC10824109
- DOI: 10.4251/wjgo.v16.i1.110
Clinical value of oral contrast-enhanced ultrasonography in diagnosis of gastric tumors
Abstract
Background: The incidence of gastric cancer remains high, and it is the sixth most common cancer and the fourth leading cause of cancer deaths worldwide. Oral contrast-enhanced ultrasonography is a simple, non-invasive, and painless method for the diagnosis of gastric tumors.
Aim: To explore the diagnostic value of oral contrast-enhanced ultrasonography for the detection of gastric tumors.
Methods: The screening results based on oral contrast-enhanced ultrasonography and electronic gastroscopy were compared with those of the postoperative pathological examination.
Results: Among 42 patients with gastric tumors enrolled in the study, the diagnostic accordance rate was 95.2% for oral contrast-enhanced ultrasonography (n = 40) and 90.5% for electronic gastroscopy (n = 38) compared with postoperative pathological examination. The Kappa value of consistency test with pathological findings was 0.812 for oral contrast-enhanced ultrasonography and 0.718 for electronic gastroscopy, and there was no significant difference between them (P = 0.397). For the TNM staging of gastric tumors, the accuracy rate of oral contrast-enhanced ultrasonography was 81.9% for the overall T staging and 50%, 77.8%, 100%, and 100% for T1, T2, T3, and T4 staging, respectively. The sensitivity and specificity were both 100% for stages T3 and T4. The diagnostic accuracy rate of oral contrast-enhanced ultrasonography was 93.8%, 80%, 100%, and 100% for stages N0, N1-N3, M0, and M1, respectively.
Conclusion: The accordance rate of qualitative diagnosis by oral contrast-enhanced ultrasonography is comparable to that of gastroscopy, and it could be used as the preferred method for the early screening of gastric tumors.
Keywords: Controlled study; Diagnosis; Electronic gastroscopy; Gastric tumor; Oral contrast-enhanced ultrasonography; Pathological examination.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: There is no conflict of interest to disclose.
Figures
References
-
- Wang LA, Wei X, Li Q, Chen L. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. Tumour Biol. 2016;37:7327–7332. - PubMed
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
-
- Willis S, Truong S, Gribnitz S, Fass J, Schumpelick V. Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy. Surg Endosc. 2000;14:951–954. - PubMed
-
- Badea R, Neciu C, Iancu C, Al Hajar N, Pojoga C, Botan E. The role of i.v. and oral contrast enhanced ultrasonography in the characterization of gastric tumors. A preliminary study. Med Ultrason. 2012;14:197–203. - PubMed
-
- Habermann CR, Weiss F, Riecken R, Honarpisheh H, Bohnacker S, Staedtler C, Dieckmann C, Schoder V, Adam G. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology. 2004;230:465–471. - PubMed
LinkOut - more resources
Full Text Sources
